NCT06682806Phase 2Terminated

A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Study sponsor: Prelude Therapeutics Incorporated

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-01-23Actual
Enrollment · participants6Actual
Source updated2026-02-02Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 4 fields changed

Actual enrollment decreased by 1 participants

Before: 7 participants (actual). After: 6 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Aug 2027. After: 23 Jan 2026.

Recruitment status changed

Before: Active not recruiting. After: Terminated.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview